Research Article

Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy

Zhuo Wang,1 Liqun Zhang,1,2 Jingyan Wang,3 Yuanhe Wang,1 Qian Dong,1 Haiyan Piao,1 Qiwei Wang,1 and Jingdong Zhang1

1Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, No. 44 Xiaoheyan Road, Dadong District, Shenyang, 110042 Liaoning Province, China
2Department of Medical Oncology, Shenyang Fifth People Hospital, Tiexi District, Shenyang, 110020 Liaoning Province, China
3Department of Medical Oncology, Liaohua Hospital, Hongwei District, Liaoyang, 111003 Liaoning Province, China

Correspondence should be addressed to Jingdong Zhang; jdzhang@cancerhosp-ln-cmu.com

Received 28 February 2020; Revised 16 July 2020; Accepted 17 July 2020; Published 5 August 2020

Abstract

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide [1]. Through surgery, systemic treatments, and growing stress on multidisciplinary evaluation and treatment of patients, the 5-year net survival rate of GC is generally in the range of 25–30%. However, the median overall survival (OS) of patients with unresectable GC is only 9–11 months with combination cytotoxic chemotherapy as the global standard of care [2]. The human epidermal growth factor receptor (HER)-2 status can be used to predict the effect of targeted therapy and the prognosis. Although the median OS of patients with HER-2-positive GC is extended to 14–16 months with addition of trastuzumab in backbone chemotherapy, patients with HER-2 gene amplification or protein

1. Introduction

Although gastric cancer (GC) is the fifth most common cancer, it is the third leading cause of cancer-related mortality worldwide [1]. Through surgery, systemic treatments, and growing stress on multidisciplinary evaluation and treatment of patients, the 5-year net survival rate of GC is generally in the range of 25–30%. However, the median overall survival (OS) of patients with unresectable GC is only 9–11 months with combination cytotoxic chemotherapy as the global standard of care [2]. The human epidermal growth factor receptor (HER)-2 status can be used to predict the effect of targeted therapy and the prognosis. Although the median OS of patients with HER-2-positive GC is extended to 14–16 months with addition of trastuzumab in backbone chemotherapy, patients with HER-2 gene amplification or protein
overexpression account for only 20% of the overall GC population [3, 4]. The Union for International Cancer Control recommends the tumor-node-metastasis (TNM) classification for GC. However, its predictive value remains deficient, particularly for patients with advanced GC, who have lost the chance for radical surgery. Therefore, there is an increasing demand for novel predictors of the chemotherapy response and survival period in patients with unresectable GC, which will aid physicians by facilitating decision-making in identifying appropriate patients for chemotherapy programs.

The therapeutic effect and prognosis of patients with cancer may be related to their inflammatory and nutritional status. Proinflammatory chemokines and cytokines participate in the occurrence, development, recurrence, and metastasis of tumors, and reduce the effectiveness of cytotoxic drugs, ultimately affecting the prognosis [5, 6]. Additionally, patients with cancer are prone to malnutrition, which reduces their tolerance of cancer treatment and the likelihood of response, and is an independent predictor of poor outcome [7]. Among the inflammation- and nutrition-related biomarkers, relevant research has proven that the albumin-to-globulin ratio (AGR), fibrinogen-to-albumin ratio (FAR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) have a significant prognostic value in patients with cancer receiving cytotoxic drug therapy [8–12].

Albumin and globulin alone can develop into indicators of the patients’ prognosis. However, albumin and globulin test results are affected by various factors, including physiological and pathological changes. Studies have combined albumin and globulin as predictors to minimize the impact of an isolated value on the result. Numerous studies have reported a relationship between the pretreatment AGR and the treatment response in patients with GC [13–15]. Compared with albumin, prealbumin has a shorter half-life and a lower plasma concentration [16]. Even minor changes in the nutritional status can be detected by the prealbumin level, which may make prealbumin a potential prognostic factor superior to albumin [17]. In a recent study, it was found that the prealbumin-to-globulin ratio (PGR) can indicate the chemotherapy efficacy and the prognosis of patients with cancer [18]. However, the analysis of the PGR performed in patients with GC was relatively limited.

The main objective of this study was to evaluate whether the pretreatment PGR could develop into a marker of chemotherapy response and a prognostic marker for the progression-free survival (PFS) and OS in patients with unresectable GC receiving first-line chemotherapy. We also compared the PGR with the AGR to determine which is a better prognostic indicator. Thus, this study investigated two potential prognostic factors, the PGR and AGR.

2. Materials and Methods

2.1. Patient Selection and Follow-Up. We retrospectively reviewed the records of patients with nonresectable GC evaluated from January 2013 to January 2018 at the Cancer Hospital of the China Medical University in Shenyang City, Liaoning Province, China.

The following were the enrollment criteria: (1) chemotherapy-naive, stage III–IV unresectable gastric adenocarcinoma diagnosed by biopsy and imaging; (2) an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2; (3) no severe complications that may hinder patients from receiving chemotherapy; (4) completed at least two cycles of chemotherapy; and (5) completed all required blood tests within 1 week before the initial first-line chemotherapy. We excluded patients with kidney or liver diseases other than tumors and those with severe chronic or acute inflammatory diseases.

Radiographic assessments were performed at baseline and every 6–8 weeks until disease progression. After the failure of first-line chemotherapy, the patients were followed up every 8–12 weeks until they died. Variations of approximately 1 week were regarded as a permissible error.

All enrolled patients volunteered to participate in the study, which was approved by the Ethics Committee of the Cancer Hospital of China Medical University.

2.2. Clinical Data Collection. We collected the following data from the hospital records: the patients’ characteristics before first-line chemotherapy, the location of the tumor in the stomach as determined by gastroscopy, and computed tomography (CT)-, magnetic resonance imaging (MRI)-, and positron emission tomography (PET)/CT-determined metastatic lymph nodes and organs. Peripheral blood analysis and albumin, prealbumin, globulin, hemoglobin, carci-noembryonic antigen (CEA), carbohydrate antigen 72-4 (CA72-4), and carbohydrate antigen 19-9 (CA19-9) levels were obtained within 1 week of treatment initiation. The reference ranges for plasma albumin, prealbumin, globulin, and hemoglobin were 35–50 g/L, 160–450 mg/L, 20–35 g/L, and 115–155 g/L, respectively. The accepted normal ranges of CEA, CA72-4, and CA19-9 were 0–5 ng/ml, 0–6 U/ml, and 0–37 U/ml, respectively. The PGR and AGR were defined as prealbumin (mg/L)/globulin (g/L) ratio and albumin (g/L)/globulin (g/L) ratio, respectively.

All patients received different systemic first-line chemotherapy regimens depending on their ECOG score. Patients were evaluated for therapy response after every two cycles of chemotherapy. We adopted the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) to assess the patients’ chemotherapy response, as follows: complete remission (CR), partial response (PR), stable disease (SD), and disease progression. The objective response rate (ORR) was calculated as CR + PR. The disease control rate (DCR) was calculated as CR + PR + SD. The PFS was defined as the period from first-line chemotherapy until disease progression or death as a result of any cause, whichever occurred first, and the OS was defined as the period from the date of first-line chemotherapy to the date of death from any cause.

2.3. Data Analysis Methods. The Statistical Package for Social Sciences version 25 software (SPSS Inc., Chicago, IL, USA) was used for data analysis. We used the cut-off values of the PGR and AGR determined by a receiver operating characteristic curve analysis to divide all patients with unresectable GC into high-value and low-value groups for each factor. Fisher’s
exact test and the chi-square test were used to evaluate the relationship between the PGR or AGR and the patients’ characteristics and therapeutic response. Kaplan-Meier’s method was used to plot the PFS and OS curves, and the PFS and OS were analyzed using the log-rank test. Pearson’s correlation analysis was employed to assess the linear correlation between the prognostic factors and the PFS and OS. Univariate and multivariate analyses were performed using a Cox proportional hazards model to identify potential predictors of mortality. We verified that the proportional hazards assumption was met [19]. In the proportional hazards assumption, we classified patients into two groups based on the following criteria: (1) median age of 60 years; (2) body mass index less than 18.5 or greater than 25 kg/m², CEA >5 ng/mL, CA72-4 >6 U/mL, CA19-9 >37 U/mL, and hemoglobin <115 g/L; abnormal values that may be associated with a poor patient prognosis; and (3) compared with those with ECOG scores 0–1, papillary or tubular adenocarcinoma, TNM stage III, number of tumor organ metastases 0–1, and no peritoneal metastasis, patients with ECOG ≥2, poorly cohesive or mucinous adenocarcinoma, TNM stage IV, number of tumor organ metastases ≥2, and peritoneal metastasis may have a worse prognosis. Those variables that were clinically and statistically significant in the univariate analysis were included in multivariate Cox regression models. A p value <0.05 was considered statistically significant.

3. Results

3.1. Identification of the Optimal Cut-off Value for the PGR and AGR. The median PFS of 151 days was the state variable, the PGR and AGR were used as the test variables, and then, the cut-off values of the above two prognostic components were determined. We found that a PGR of 7.205 and an AGR of 1.455 were the strongest prognostic factors for the PFS. The area under the curve (AUC) values for the PGR and AGR were 0.660 (95% confidence interval [CI]: 0.597–0.723, sensitivity = 0.624, specificity = 0.614, p < 0.001) and 0.707 (95% CI: 0.646–0.769, sensitivity = 0.752, specificity = 0.664, p < 0.001), respectively. From the results, the AUC value of the AGR was slightly larger than that of the PGR; thus, the AGR may be better than the PGR for predicting the prognosis of patients. In this study, we set the cut-off values for the
PGR and AGR to 7.21 and 1.46, respectively. Patients with a PGR ≥ 7.21 and an AGR ≥ 1.46 were categorized in the high-PGR and high-AGR groups, respectively; otherwise, they were categorized in the low-PGR and low-AGR groups, respectively (Figure 1).

3.2. Clinicopathological Features. A total of 281 patients with advanced GC receiving first-line chemotherapy were included in the analysis. The majority of patients were men (66.55%), and the median age of the patients was 60 years. Among all, 74.38% and 82.92% of patients had a normal body mass index and an ECOG score less than 2 points, respectively. Patients with poorly cohesive or mucinous adenocarcinoma (74.02%) and stage IV disease (80.43%) represented the highest proportions among all patients. The number of patients with more than one organ metastases was the same as that with peritoneal metastases, accounting for 32.38% of the total. SOX (oxaliplatin + S1)/CapeOX (oxaliplatin + capecitabine), FOLFOX (oxaliplatin + leucovorin + 5-fluorouracil), and DCF (docetaxel + cisplatin + 5-fluorouracil)/DOF (docetaxel + oxaliplatin + 5-fluorouracil) were the primary chemotherapy regimens for patients receiving first-line chemotherapy, accounting for 50.53%, 17.44%, and 10.68% of the total, respectively. Based on the RECIST1.1 criteria, the ORR and DCR were 13.17% and 86.12%, respectively. Table 1 details the characteristics of the patients.

There were some differences in terms of the histopathological and clinical parameters between the low and high groups. The analysis indicated that a low PGR (p = 0.006) and a low AGR (p = 0.001) were significantly related to a hemoglobin level <115 g/L. The probability of more than one organ metastases and peritoneal metastases was statistically higher in the low-AGR group (p = 0.029; Table 2).

Table 1: Baseline characteristics of the patients.

| Characteristics                          | Cases (n = 281) | Percentage |
|-----------------------------------------|----------------|------------|
| Sex                                     |                |            |
| Male                                    | 187            | 66.55%     |
| Female                                  | 94             | 33.45%     |
| Age (yr)                                |                |            |
| ≤60                                     | 159            | 56.58%     |
| >60                                     | 122            | 43.42%     |
| Body mass index (kg/m²)                 |                |            |
| <18.5 or >25                            | 72             | 25.62%     |
| 18.5–25                                 | 209            | 74.38%     |
| ECOG                                    |                |            |
| 0–1                                     | 233            | 82.92%     |
| ≥2                                      | 48             | 17.08%     |
| Histological type                       |                |            |
| Papillary, tubular,                     | 73             | 25.98%     |
| Poorly cohesive, mucinous               | 208            | 74.02%     |
| TNM stage                               |                |            |
| III                                     | 55             | 19.57%     |
| IV                                      | 226            | 80.43%     |
| Number of organs affected by metastasis |                |            |
| 0–1                                     | 190            | 67.62%     |
| ≥2                                      | 91             | 32.38%     |
| Peritoneal metastasis                   |                |            |
| Yes                                     | 91             | 32.38%     |
| No                                      | 190            | 67.62%     |
| First-line chemotherapy regimen         |                |            |
| SOX/CapeOX                              | 142            | 50.53%     |
| FOLFOX                                  | 49             | 17.44%     |
| DCF/DOF                                 | 30             | 10.68%     |
| Capecitabine/S-1                        | 22             | 7.83%      |
| Others                                  | 38             | 13.52%     |
| Best response                           |                |            |
| Complete remission                      | 0              | —          |
| Partial response                        | 37             | 13.17%     |
| Stable disease                          | 205            | 72.95%     |
| Progression of disease                  | 39             | 13.88%     |
| Objective response rate                 | 37             | 13.17%     |
| Disease control rate                    | 242            | 86.12%     |
| Tumor biomarkers                        |                |            |
| CEA >5 ng/mL                            | 121            | 43.06%     |
| CA72-4 >6 U/mL                          | 158            | 56.23%     |
| CA19-9 >37 U/mL                         | 106            | 37.72%     |
| Hemoglobin (g/L)                        |                |            |
| <115                                    | 105            | 37.37%     |
| ≥115                                    | 176            | 62.63%     |
| Albumin (g/L)                           |                |            |
| <35                                     | 52             | 18.51%     |
| ≥35                                     | 229            | 81.49%     |

Table 1: Continued.

| Characteristics                          | Cases (n = 281) | Percentage |
|-----------------------------------------|----------------|------------|
| Prealbumin (mg/L)                       |                |            |
| <160                                    | 83             | 29.54%     |
| ≥160                                    | 198            | 70.46%     |
| Globulin (g/L)                          |                |            |
| ≤35                                     | 259            | 92.17%     |
| >35                                     | 22             | 7.83%      |
| PGR                                      |                |            |
| <7.21                                   | 139            | 49.47%     |
| ≥7.21                                   | 142            | 50.53%     |
| AGR                                      |                |            |
| <1.46                                   | 128            | 45.55%     |
| ≥1.46                                   | 153            | 54.45%     |

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; SOX: oxaliplatin + S1; CapeOX: oxaliplatin + capecitabine; FOLFOX: oxaliplatin + leucovorin + 5-fluorouracil; DCF: docetaxel + cisplatin + 5-fluorouracil; DOF: docetaxel + oxaliplatin + 5-fluorouracil; CEA: carcinoembryonic antigen; CA72-4: carbohydrate antigen 72-4; CA19-9: carbohydrate antigen 19-9; PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio.
3.3. Relationship between the PGR and AGR and the First-Line Chemotherapy Response. We evaluated the relationship between the PGR and AGR levels before receiving first-line chemotherapy and the treatment response. Patients in the high-PGR (93.66% vs. 78.42%, \( p < 0.001 \)) and high-AGR (94.12% vs. 76.56%, \( p < 0.001 \)) groups had a higher DCR than that of those in the low-groups. The high-AGR group had an ORR nearly two times higher than that of the low-AGR group (16.99% vs. 8.59%, \( p = 0.038 \)). Although patients in the high-PGR group tended to have a higher ORR, the difference did not reach statistical significance (15.49% vs. 10.79%, \( p = 0.244 \)). These findings indicate that the AGR may be superior to the PGR in predicting chemotherapy response (Table 3).

3.4. Survival Analysis according to the Pretreatment PGR and AGR. Figures 2 and 3 show the Kaplan-Meier curves for survival. The validity of the proportional hazards assumption for

| Table 2: Relationship between the pretreatment PGR and AGR and clinicopathological factors. |
|----------------------------------|------------------|------------------|------------------|------------------|------------------|
|                                | Low  | High | \( p \) value | Low  | High | \( p \) value |
|--------------------------------|------|------|--------------|------|------|--------------|
| **Sex**                        |      |      |              |      |      |              |
| Male                           | 95   | 92   | 0.528        | 86   | 101  | 0.835        |
| Female                         | 44   | 50   |              | 42   | 52   |              |
| **Age (yr)**                   |      |      |              |      |      |              |
| >60                            | 63   | 59   | 0.523        | 61   | 61   | 0.190        |
| \( \leq 60 \)                  | 76   | 83   |              | 67   | 92   |              |
| **Body mass index (kg/m\(^2\))** |      |      |              |      |      |              |
| <18.5 or >25                   | 40   | 32   | 0.231        | 30   | 42   | 0.443        |
| 18.5–25                        | 99   | 110  |              | 98   | 111  |              |
| **ECOG**                       |      |      |              |      |      |              |
| 0–1                            | 113  | 120  | 0.474        | 104  | 129  | 0.497        |
| \( \geq 2 \)                   | 26   | 22   |              | 24   | 24   |              |
| **Histological type**          |      |      |              |      |      |              |
| Papillary, tubular             | 35   | 38   | 0.763        | 27   | 46   | 0.088        |
| Poorly cohesive, mucinous      | 104  | 104  |              | 101  | 107  |              |
| **TNM stage**                  |      |      |              |      |      |              |
| III                            | 26   | 29   | 0.717        | 21   | 34   | 0.221        |
| IV                             | 113  | 113  |              | 107  | 119  |              |
| **Number of organs affected by metastasis** |      |      |              |      |      |              |
| 0–1                            | 90   | 100  | 0.309        | 78   | 112  | 0.029        |
| \( \geq 2 \)                   | 49   | 42   |              | 50   | 41   |              |
| **Peritoneal metastasis**      |      |      |              |      |      |              |
| Yes                            | 52   | 39   | 0.075        | 50   | 41   | 0.029        |
| No                             | 87   | 103  |              | 78   | 112  |              |
| **CEA (ng/mL)**                |      |      |              |      |      |              |
| >5                             | 67   | 54   | 0.085        | 56   | 65   | 0.831        |
| \( \leq 5 \)                   | 72   | 88   |              | 72   | 88   |              |
| **CA72-4 (U/mL)**              |      |      |              |      |      |              |
| >6                             | 79   | 79   | 0.839        | 76   | 82   | 0.331        |
| \( \leq 6 \)                   | 60   | 63   |              | 52   | 71   |              |
| **CA19-9 (U/mL)**              |      |      |              |      |      |              |
| >37                            | 59   | 47   | 0.106        | 52   | 54   | 0.359        |
| \( \leq 37 \)                  | 80   | 95   |              | 76   | 99   |              |
| **Hemoglobin (g/L)**           |      |      |              |      |      |              |
| <115                           | 63   | 42   | 0.006        | 61   | 44   | 0.001        |
| \( \geq 115 \)                 | 76   | 100  |              | 67   | 109  |              |

PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio; ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbohydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9.
the model was assessed via log(−log[survival]) plots. In the whole group, the patients’ median PFS and OS were 151 and 322 days, respectively. The high-PGR group had longer median PFS (189 vs. 125 days, \( p < 0.001 \)) and median OS (350 vs. 288 days, \( p < 0.001 \)) than those of the low-PGR group. Compared with the low-AGR group, the high-AGR group had median extended PFS (206 vs. 112 days, \( p < 0.001 \)) and median OS (359 vs. 269 days, \( p < 0.001 \)).

Pearson’s correlation analysis indicated that the PGR and AGR values were positively correlated with the PFS and OS in patients with GC (all \( p < 0.001 \); Figure 4).

3.5. Prognostic Factors Influencing the Long-Term Survival.

The univariate and multivariate analyses estimated the factors affecting the PFS and OS (Tables 4 and 5). The univariate Cox regression analyses revealed that the high-PGR group had longer PFS (hazard ratio [HR]: 0.644; 95% CI: 0.508–0.817; \( p < 0.001 \)) and OS (HR: 0.644; 95% CI: 0.507–0.817; \( p < 0.001 \)) compared with the low-PGR group. Analogous results were found in the high-AGR group. After adjusting for the effects of the prognostic factors in the multivariate analysis, the high-PGR group was still strongly associated with prolonged PFS (HR: 0.672; 95% CI: 0.527–0.857; \( p = 0.001 \)) and OS (HR: 0.675; 95% CI: 0.530–0.861; \( p = 0.002 \)), as was the high-AGR group. Regarding the other prognostic elements in the multivariate analysis, poorly cohesive or mucinous adenocarcinoma, more than one organ affected by metastasis, and CA72-4 >6 U/mL were associated with limited PFS, and poorly cohesive or mucinous adenocarcinoma, peritoneal dissemination, CEA >5 ng/mL were associated with unfavorable OS (all \( p < 0.05 \)).

4. Discussion

Systemic inflammation and malnutrition are prevailing in patients with cancer. These factors have a significant impact on the patients’ quality of life, treatment outcomes, diagnosis, and durability, and may increase the risk of longer duration of hospitalization, infection, treatment toxicity, and treatment costs [5, 7, 20, 21]. These effects are also manifested in patients with GC, particularly those with advanced cancer. Patients with gastrointestinal tumors are more likely to suffer from gastrointestinal obstruction and malabsorption and other complications. Hence, early detection of inflammation and malnutrition is crucial. However, medical workers tend to belittle this fact during anticancer treatment, making it imperative to appraise the inflammatory and nutritional status of patients with cancer.

Multiple studies have investigated a series of inflammatory and nutritional markers available to doctors, including the PGR, AGR, FAR, PLR, NLR, and LMR, for the prognosis of patients with different types of cancer [18, 22–26]. Among them, the AGR, FAR, PLR, NLR, and LMR were frequently applied to anticipate complications and the prognosis of patients with GC [27–31]. However, there is scant evidence on the relationship between the PGR and the prognosis of patients with GC.

In this study, we explored the prognostic and predictive role of the PGR in patients with GC receiving first-line chemotherapy. First, we found that a low pretreatment PGR was strongly associated with a hemoglobin level of <115 g/L. A previous study has shown that patients with GC who have anemia have a poor prognosis [32], which indirectly reveals that the PGR is a reliable prognostic biomarker. Next, we assessed the ability of the PGR level to predict the chemotherapy response. Patients in the high-PGR group had a higher DCR than that of those in the low-PGR groups. The high PGR value contributed to a superior ORR, but it did not achieve statistical significance. This was probably due to the small sample size. Furthermore, we found that a high PGR was significantly associated with prolonged OS and PFS in the survival analysis, and the PGR value was positively linearly correlated with the PFS and OS. Finally, the multivariate analysis revealed that the PGR was an independent prognostic indicator for the survival of patients with GC receiving chemotherapy, which further establishes a sturdy bedrock for the PGR to mature into an applicable prognostic biomarker for patients with GC. The inherent mechanisms of the PGR as a prognostic marker for patients with GC are as follows.

First, inflammatory cytokines released by inflammatory cells can cultivate an inflammatory microenvironment, which provides a hotbed for tumor growth. Therefore, chronic inflammation is a contributor to tumor cell growth, angiogenesis, development, progression, recurrence, and metastasis [5]. The level of globulin contained in the PGR may reflect the level of inflammation in patients [33]. As a chronic inflammation biochemical...
The concentration of serum globulin gradually increases when stimulated by proinflammatory cytokines, such as tumor necrosis factor-α, interleukin-6, and interleukin-1β [34]. Previous studies have shown that globulin levels are associated with shorter survival in patients [35, 36].

Second, malnutrition relates intimately to a decline in the quality of life, reducing the adherence to treatment and response to therapy. As malnutrition is one of the leading causes for immunodeficiency, the nutritional status can be used to comparatively quickly assess the host’s immune status [37, 38]. Protein-related malnutrition is universal in

Figure 2: Kaplan-Meier’s curves for progression-free survival of the PGR (a) and AGR (b) groups. Log of the negative log of the survival curve for progression-free survival of the PGR (c) and AGR (d) groups. PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio.
patients with advanced tumors receiving treatment and eventually leads to the collapse of the cellular and humoral immunity, which is known to play a central role in the defenses against malignant tumor cells. Malnutrition can affect the synthesis of prealbumin, one of the PGR components; thus, prealbumin can be used as a surrogate marker to mirror the nutritional status of patients [39]. Compared with albumin, prealbumin has a shorter half-life of 2 days and a smaller concentration in the body, which makes it susceptible to changes in the serum and an ideal candidate sensitive marker.

Figure 3: Kaplan-Meier’s curve for overall survival of the PGR (a) and AGR (b) groups. Log of the negative log of the survival curve for overall survival of the PGR (c) and AGR (d) groups. PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio.
for predicting the prognosis of patients [40]. Earlier studies have discussed the independent prognostic role of serum prealbumin [41, 42].

Finally, globulin and prealbumin are two potentially valued elements related to the prognosis of patients with cancer. However, these parameters alone are not sufficient to predict the patients’ prognosis. The globulin level is an inversely related prognostic index, while the prealbumin level is a positively related prognostic index. Integrating indicators into the PGR has improved accuracy. By calculating the ratio of globulin to prealbumin, lower values are accompanied by inflammation or/and malnutrition, which may be related to a poor prognosis. On the contrary, a higher value indicates no inflammation or/and great nutritional status, which can be associated with a favorable prognosis. Therefore, compared with globulin and prealbumin alone, the PGR probably has a better ability to distinguish patients with favorable prognosis from those with unfavorable prognosis.

This study has several strengths. We demonstrated for the first time that the PGR is a significant indicator that can independently predict the PFS and OS in patients with GC receiving first-line chemotherapy. This study was the first to use the PGR as a forecasting element of chemotherapeutic response for patients with GC.

There are also limitations to this study. First, the PGR was found not to be superior to the AGR as a prognostic indicator in this study. This might be because patients with advanced GC have gone through protracted disease history, prolonging chronic malnutrition and inflammation in these patients. Therefore, we speculate that the PGR with a shorter half-life of 2–3 days is superior to the AGR with a half-life of 21 days as a prognostic marker in early-stage patients, but further research is needed to validate this hypothesis. Second, the present was a single-center retrospective study. Hence, the usefulness of the PGR still needs to be verified by multicenter large-scale prospective studies.

Figure 4: Pearson’s correlation analysis for the linear relationship between the PGR group and progression-free survival (a) and overall survival (b); Pearson’s correlation analysis for the linear relationship between the AGR group and progression-free survival (c) and overall survival (d). PGR: Prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio.
|                              | Progression-free survival | Overall survival |
|------------------------------|---------------------------|-----------------|
|                              | Univariate analysis Hazard ratio | Multivariate analysis Hazard ratio | Univariate analysis Hazard ratio | Multivariate analysis Hazard ratio |
|--------------------------------------------------------------------------------|
| Sex (male)                    | 1.073                     | 0.835-1.379     | 0.582 | 1.145 | 0.891-1.471 | 0.290 |
| Age (>60 years)               | 0.991                     | 0.781-1.256     | 0.939 | 0.797 | 0.627-1.012 | 0.062 |
| Body mass index (<18.5 or >25 kg/m²) | 0.923                     | 0.705-1.207     | 0.558 | 1.084 | 0.828-1.420 | 0.055 |
| ECOG (≥2)                     | 1.124                     | 0.823-1.535     | 0.463 | 1.174 | 0.859-1.604 | 0.313 |
| Histological type (poorly cohesive, mucinous) | 1.492                     | 1.136-1.959     | 0.004 | 1.495 | 1.137-1.965 | 0.004 |
| TNM stage (IV)                | 1.206                     | 0.897-1.622     | 0.214 | 1.368 | 1.017-1.839 | 0.038 |
| Number of organs affected by metastasis (≥2) | 1.390                     | 1.081-1.786     | 0.010 | 1.400 | 1.077-1.818 | 0.012 |
| Peritoneal metastasis (yes)   | 1.526                     | 1.185-1.966     | <0.001 | 1.297 | 0.991-1.696 | 0.058 |
| CEA (>5 ng/mL)                | 1.222                     | 0.959-1.557     | 0.105 | 1.138 | 0.878-1.474 | 0.328 |
| CA72-4 (>6 U/mL)              | 1.425                     | 1.118-1.816     | 0.004 | 1.411 | 1.091-1.824 | 0.009 |
| CA19-9 (>37 U/mL)             | 1.051                     | 0.825-1.339     | 0.686 | 1.046 | 0.821-1.332 | 0.717 |
| Hemoglobin (<115 g/L)         | 0.905                     | 0.708-1.157     | 0.424 | 0.890 | 0.697-1.136 | 0.349 |
| PGR ≥7.21                     | 0.644                     | 0.508-0.817     | <0.001 | 0.672 | 0.527-0.857 | 0.001 |

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbohydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9; PGR: prealbumin-to-globulin ratio.
|                      | Univariate analysis | Progression-free survival | Multivariate analysis | Overall survival |
|----------------------|---------------------|---------------------------|-----------------------|------------------|
|                      | Hazard ratio        | 95% CI                    | p value               | Hazard ratio     | 95% CI            | p value           | Hazard ratio     | 95% CI            | p value           |
| Sex (male)           | 1.073               | 0.835-1.379               | 0.582                 | 1.145            | 0.891-1.471       | 0.290             |
| Age (>60 years)      | 0.991               | 0.781-1.256               | 0.939                 | 0.797            | 0.627-1.012       | 0.062             | 0.877            | 0.678-1.135       | 0.320             |
| Body mass index (<18.5 or >25 kg/m²) | 0.923 | 0.705-1.207 | 0.558 | 1.084 | 0.828-1.420 | 0.557 | |
| ECOG (≥2)            | 1.124               | 0.823-1.535               | 0.463                 | 1.174            | 0.859-1.604       | 0.313             |
| Histological type (poorly cohesive, mucinous) | 1.492 | 1.136-1.959 | 0.004 | 1.355 | 1.028-1.787 | 0.031 | |
| TNM stage (IV)       | 1.206               | 0.897-1.622               | 0.214                 | 1.368            | 1.017-1.839       | 0.038             | 1.182            | 0.852-1.640       | 0.318             |
| Number of organs affected by metastasis (≥2) | 1.390 | 1.081-1.786 | 0.010 | 1.341 | 1.030-1.746 | 0.029 | |
| Peritoneal metastasis (yes) | 1.526 | 1.185-1.966 | <0.001 | 1.239 | 0.947-1.621 | 0.118 | 1.710 | 1.325-2.205 | <0.001 | 1.419 | 1.056-1.907 | 0.020 |
| CEA (>5 ng/mL)       | 1.222               | 0.959-1.557               | 0.105                 | 1.146            | 0.883-1.487       | 0.305             | 1.278            | 1.004-1.626       | 0.046             | 1.381 | 1.066-1.787 | 0.014 |
| CA72-4 (>6 U/mL)     | 1.425               | 1.118-1.816               | 0.004                 | 1.418            | 1.093-1.840       | 0.009             | 1.254            | 0.989-1.590       | 0.061             | 1.150 | 0.891-1.485 | 0.284 |
| CA19-9 (>37 U/mL)    | 1.051               | 0.825-1.339               | 0.686                 | 1.046            | 0.821-1.332       | 0.717             |
| Hemoglobin (<115 g/L) | 0.905               | 0.708-1.157               | 0.424                 | 0.890            | 0.697-1.136       | 0.349             |
| AGR ≥1.46            | 0.419               | 0.328-0.535               | <0.001                | 0.454            | 0.353-0.583       | <0.001            | 0.584            | 0.460-0.742       | <0.001            | 0.602 | 0.472-0.769 | <0.001 |

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbohydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9; AGR: albumin-to-globulin ratio.
5. Conclusions

The prechemotherapy PGR level can predict the chemother-apy effect in patients with advanced GC and is an independent predictor of the PFS and OS. It may be a reliable prognostic tool for medical practitioners.

Data Availability

We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for noncommercial purposes, without breaching participant confidentiality.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Zhuo Wang and Liqun Zhang are co-first authors of the article.

Acknowledgments

This study was supported by the National Key R&D Program of China (grant# 2018YFC1311600), the Scientific Research Foundation For The Introduction Of Talents, Liaoning Cancer Hospital & Institute (grant# Z1702), the Science and Technology Planning Project of Liaoning Province of China (grant# 201800449), the Science and Technology Planning Project of Shenyang (grant# 191124088), and the Science and Technology Planning Project of Shenyang (grant# F15-139-9-27).

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] C. Allemani, H. K. Weir, H. Carreira et al., “Global surveillance of cancer survival 1995–2011: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2),” Lancet, vol. 385, no. 9972, pp. 977–1010, 2015.

[3] A. D. Wagner, N. L. X. Syn, M. Moehler et al., “Chemotherapy for advanced gastric cancer,” The Cochrane Database of Systenatic Reviews, vol. 8, 2017Cd004064.

[4] E. Van Cutsem, Y.-J. Bang, F. Feng-yi et al., “HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer,” Gastric Cancer, vol. 18, no. 3, pp. 476–484, 2015.

[5] E. Elinav, R. Nowarski, C. A. Thaiss, B. Hu, C. Jin, and R. A. Flavell, “Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms,” Nature reviews Cancer, vol. 13, no. 11, pp. 759–771, 2013.

[6] C. Vajaitu, C. C. Draghici, I. Solomon et al., “The central role of inflammation associated with checkpoint inhibitor treat-ments,” Journal of Immunology Research, vol. 2018, Article ID 4625472, 10 pages, 2018.

[7] A. J. V. Vandenbroeck and D. Schrijvers, “Nutritional issues in anti-cancer treatment,” Annals of Oncology, vol. 19, pp. v52–v55, 2008.

[8] G. Y. Lv, L. An, X. D. Sun, Y. L. Hu, and D. W. Sun, “Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: a meta-analysis,” Clinica Chimica Acta, vol. 476, pp. 81–91, 2018.

[9] Q. Xu, Y. Yan, S. Gu et al., “A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma,” Journal of Immunology Research, vol. 2018, Article ID 4925498, 11 pages, 2018.

[10] Y. G. Tan, E. W. C. Eu, H. H. Huang, and W. K. O. Lau, “High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer,” International Journal of Urology, vol. 25, no. 3, pp. 232–238, 2018.

[11] J. Huszno, Z. Kolosza, J. Mrochem-Kwaciak, T. Rutkowski, and K. Skladowski, “The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma,” Oncology, vol. 97, no. 1, pp. 7–17, 2019.

[12] A. Yamamoto, Y. Toiyama, Y. Okugawa et al., “Clinical implications of pretreatment: lymphocyte-to-monocyte ratio in patients with rectal cancer receiving preoperative chemoradiotherapy,” Diseases of the Colon & Rectum, vol. 62, no. 2, pp. 171–180, 2019.

[13] M. J. Mao, X. L. Wei, H. Sheng et al., “Clinical significance of preoperative albumin and globulin ratio in patients with gastric cancer undergoing treatment,” BioMed Research International, vol. 2017, Article ID 3083267, 8 pages, 2017.

[14] S. Xiao, F. Feng, N. Liu et al., “Preoperative albumin level is superior to albumin-globulin ratio as a predicting Indicator in gastric cancer patients who underwent curative resection,” Cancer Management and Research, vol. 11, pp. 9931–9938, 2019.

[15] Y. Bozkaya, G. U. Erdem, N. S. Demirci et al., “Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients,” Current Medical Research and Opinion, vol. 35, no. 2, pp. 275–282, 2019.

[16] N. Collins, “The difference between albumin and prealbumin,” Advances in Skin & Wound Care, vol. 14, no. 5, pp. 235–236, 2001.

[17] R. R. Jia, J. H. Zhong, R. R. Huo et al., “Correlation between serum prealbumin and prognosis of patients with hepatocellular carcinoma after hepatectomy,” Journal of Surgical Oncology, vol. 119, no. 6, pp. 794–800, 2019.

[18] L. Zhang, J. Zhang, Y. Wang et al., “Potential prognostic factors for predicting the chemotherapeutic outcomes and prognosis of patients with metastatic colorectal cancer,” Journal of Clinical Laboratory Analysis, vol. 33, no. 8, article e22958, 2019.

[19] F. E. Harrell Jr., K. L. Lee, and D. B. Mark, “Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors,” Statistics in Medicine, vol. 15, no. 4, pp. 361–387, 1996.

[20] L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
[21] J. Alexandre, M. Gross-Goupil, B. Falissard et al., “Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy,” *Annals of Oncology*, vol. 14, no. 1, pp. 36–41, 2003.

[22] B. Suh, S. Park, D. W. Shin et al., “Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults,” *Annals of Oncology*, vol. 25, no. 11, pp. 2260–2266, 2014.

[23] Y. Y. Wang, Z. Z. Liu, D. Xu, M. Liu, K. Wang, and B. C. Xing, “Fibrinogen-albumin ratio index (FARI): a more promising inflammation-based prognostic marker for patients undergoing hepatectomy for colorectal liver metastases,” *Annals of Surgical Oncology*, vol. 26, no. 11, pp. 3682–3692, 2019.

[24] B. Li, P. Zhou, Y. Liu et al., “Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis,” *Clinica Chimica Acta*, vol. 483, pp. 48–56, 2018.

[25] M. Tampa, M. I. Mitran, C. I. Mitran et al., “Mediators of inflammation - a potential source of biomarkers in oral squamous cell carcinoma,” *Journal of Immunology Research*, vol. 2018, Article ID 1061780, 12 pages, 2018.

[26] M. Kawai, S. Hirono, K. I. Okada et al., “Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer,” *Surgery*, vol. 165, no. 6, pp. 1151–1160, 2019.

[27] Y. Zhang, J. Y. Zhu, L. N. Zhou, M. Tang, M. B. Chen, and M. Tao, “Predicting the prognosis of gastric cancer by albumin/globulin ratio and the prognostic nutritional index,” *Nutrition and Cancer*, vol. 72, no. 4, pp. 635–644, 2020.

[28] X. You, Q. Zhou, J. Song, L. Gan, J. Chen, and H. Shen, “Preoperative albumin-to-fibrinogen ratio predicts severe postoperative complications in elderly gastric cancer subjects after radical laparoscopic gastrectomy,” *BMC Cancer*, vol. 19, no. 1, p. 931, 2019.

[29] L. X. Zhang, Z. J. Wei, A. M. Xu, and J. H. Zang, “Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study,” *International Journal of Surgery*, vol. 56, pp. 320–327, 2018.

[30] R. Miyamoto, S. Inagawa, N. Sano, S. Tadano, S. Adachi, and M. Yamamoto, “The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients,” *European Journal of Surgical Oncology*, vol. 44, no. 5, pp. 607–612, 2018.

[31] S. Song, C. Li, S. Li, H. Gao, X. Lan, and Y. Xue, “Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer,” *Oncotargets and Therapy*, vol. 10, pp. 3145–3154, 2017.

[32] X. Z. Huang, Y. C. Yang, Y. Chen et al., “Preoperative anemia or low hemoglobin predicts poor prognosis in gastric cancer patients: a meta-analysis,” *Disease Markers*, vol. 2019, Article ID 7606128, 9 pages, 2019.

[33] E. W. Gelfand, “Intravenous immune globulin in autoimmune and inflammatory diseases,” *New England Journal of Medicine*, vol. 367, no. 21, pp. 2015–2025, 2012.

[34] C. Gabay and I. Kushner, “Acute-phase proteins and other systemic responses to inflammation,” *New England Journal of Medicine*, vol. 340, no. 6, pp. 448–454, 1999.